1. Home
  2. ORMP vs VTGN Comparison

ORMP vs VTGN Comparison

Compare ORMP & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oramed Pharmaceuticals Inc.

ORMP

Oramed Pharmaceuticals Inc.

HOLD

Current Price

$4.80

Market Cap

197.6M

Sector

Health Care

ML Signal

HOLD

Logo VistaGen Therapeutics Inc.

VTGN

VistaGen Therapeutics Inc.

HOLD

Current Price

$0.32

Market Cap

10.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ORMP
VTGN
Founded
2002
1998
Country
United States
United States
Employees
13
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
197.6M
10.8M
IPO Year
2010
2014

Fundamental Metrics

Financial Performance
Metric
ORMP
VTGN
Price
$4.80
$0.32
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
★ $0.90
AVG Volume (30 Days)
172.3K
★ 17.4M
Earning Date
05-14-2026
06-16-2026
Dividend Yield
★ 6.51%
N/A
EPS Growth
★ 412.50
N/A
EPS
★ 2.76
N/A
Revenue
★ $2,000,000.00
N/A
Revenue This Year
N/A
$124.49
Revenue Next Year
N/A
$353.99
P/E Ratio
$1.71
★ N/A
Revenue Growth
★ 49.25
N/A
52 Week Low
$2.09
$0.20
52 Week High
$5.47
$5.14

Technical Indicators

Market Signals
Indicator
ORMP
VTGN
Relative Strength Index (RSI) 49.56 69.75
Support Level $4.54 $0.22
Resistance Level $5.01 $0.66
Average True Range (ATR) 0.13 0.03
MACD -0.03 0.01
Stochastic Oscillator 33.33 35.46

Price Performance

Historical Comparison
ORMP
VTGN

About ORMP Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.

About VTGN VistaGen Therapeutics Inc.

Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.

Share on Social Networks: